



ONCOLOGY

PATIENT DETAILS

(In BLOCK letters)

Full Name

Age ^Y / ^M

Gender M F

Ethnicity

E-mail ID

Contact No.

Address

City / State / Postal Code

Country

TREATING PHYSICIAN INFORMATION

Facility Name

Physician Name

Facility Address

City / State / Postal Code

Country

E-mail ID

Contact No.

Additional Physician to be Copied(optional)

Facility Name

E-mail ID

Contact No.

CURRENT DIAGNOSIS/ PATIENT HISTORY

Diagnosis : NSCLC Melanoma Colorectal Adenocarcinoma Ovarian Breast
 Other

Disease Status (select as many as apply) : Metastatic Recurrent Refractory Relapse

Subtype

Stage

Radiological findings :

Immunohistochemistry study report :

ER, PR, Her2 neu status :

Earlier genomic tests /Targeted Therapies/ (Please mention the results)
.....
.....

Please attach the below reports to the TRF : (if Available)

Attachments :

Copy of recent pathology /cytology reports including (if available)

Test results from all other Molecular Diagnostic Assays by FISH, IHC, or other genetic assays, e.g.,ER, PR, HER2, EGFR, KRAS,etc.



TEST REQUISITION FORM

TEST SELECTION

(Sample Type)

OncoCEPT Solid (*FFPE block containing tumor tissue)

OncoCEPT Liquid (*10ml Whole blood EDTA in streck tube)

OncoCEPT Comprehensive (*FFPE block containing tumor tissue)

MSI (*FFPE blocks with slides + EDTA blood)

ColoComprehensive (MSI+BRAF+KRAS+NRAS) (*FFPE block containing tumor tissue)

MMR by IHC

PDL-1 test **PDL1 SP142** **PDL1 SP 263** **PDL1 22C3 DAKO** (#Drug details)

OncoCEPT Solid + PDL1

OncoCEPT Solid Comprehensive + PDL1

BRCA1 & BRCA2 gene sequencing

Inherited cancer panel

Other test : Description of test & sample type

In case of inadequate tissue, please tick the test which test would you like us to do first:

OncoCEPT Solid

OncoCEPT Solid Comprehensive

PDL-1

Drug details for PDL-1 IHC

(PDL-1 IHC indicated in patients with specific tumor type in order to predict their responses to treatment with PDL-1 inhibitors. The specific PDL-1 clone scoring method and eligibility requirements are dependent on the tumor type, stage of malignancy, previous treatment outcomes and specific PDL-1 inhibitors being considered)

Tick	Clone	Drug
<input type="checkbox"/>	Sp263	Nivolumab (opdivo)
<input type="checkbox"/>	Sp263	Durvalumab (imfinzi)
<input type="checkbox"/>	Sp142	Atezolilumab (Tecentriq)
<input type="checkbox"/>	Sp142	Atezolilumab (Tecentriq)
<input type="checkbox"/>	Sp142	Atezolilumab (Tecentriq) Plus nab- paclitaxel (Abaxane)
<input type="checkbox"/>	22C3 DAKO	Pembrolizumab (Keytruda)

SAMPLE DETAILS

Date of Collection (MM/DD/YYYY) **Specimen ID**

FFPE of tumour tissue (BIOPSY fixed in 10% Neutral buffered formalin)

Specimen Site

No. of paraffin blocks and details:

Please mention block number on which test has to be performed

Body Fluid (At least 1 litre) or cell block

FFPE BLOCK of tumor tissue (BIOPSY fixed in 10% Neutral buffered formalin) with HE stained slide

Specimen Site

Unstained poly L lysine coated slides

Cold ischaemia time - mins or hrs or unknown (As time of transfer of tissue after removal from body upto immersion into the 10% neutral buffered formalin)

Time Formalin fixation (10% neutral buffered formalin): known: hours / unknown

(Note : Neuberg Center for Genomic Medicine (NCGM) chooses the best block(s) based on initial morphologic assessment for further IHC PDL-1 study . It makes all efforts are made to preserve and make sure not to exhaust the tissue entirely under study. However in small thin/tiny specimen, there is a possibility of exhausting the tissue to ensure quality and reliability of the results.)

(CAP/ASCO recommendation: for breast markers and GI Her2neu, the cold ischemic time should be < 01 hours and optimal fixation for ER/PgR/Her2Neu in 10% buffered formalin MUST be 06 to 72 hours)

Family History of any Cancer

Sr. No.	Type of Cancer	Age of diagnosis	Relationship with patient	Mother's or father's side	Histopathology / genetic test reports (if available)

Billing Information

Self pay in cash (reference) _____

 Electronic payment (reference) _____



CONSENT/ASSENT FORM

PHYSICIAN CONSENT

I certify that I am patient's treating physician and I consent that this test will aid in patient's ongoing treatment. I have explained the patient about nature and purpose of testing. Patient has given his consent to me for Neuberg Center of Genomic Medicine to

- (1) Perform tests mentioned here.
- (2) Retain the test results.
- (3) De-identify the test report/ result for future research purpose and publication.

I authorize Neuberg Center of Genomic Medicine to perform most appropriate test based on submitted histopathology report.

Signature

Printed Name

Date: DD/MM/YY

PATIENT CONSENT

I certify that I have been explained by my physician that this test will aid in my ongoing treatment/management. I have been explained about nature and purpose of testing. I give my consent to Neuberg Center of Genomic Medicine to

- (1) Perform tests mentioned here.
- (2) Retain the test results.
- (3) De-identify the test report/ result for future research purpose and publication.

I authorize Neuberg Center of Genomic Medicine to perform most appropriate test based on submitted histopathology report.

Signature

Printed Name

Date: DD/MM/YY

Neuberg Centre for Genomic Medicine (NCGM)

Near GTPL House, Opp. Armedia, Sindhu Bhavan Road, Bodakdev, Ahmedabad 380059
Phone: +91-6357244307, 079-61618111 | Email: contact@ncgmglobal.com | Web: www.ncgmglobal.com